DUSA Pharmaceuticals, Inc. to Host Fourth Quarter and Full Year 2006 Financial Results and Corporate Highlights Conference Call

DUSA PHARMACEUTICALS, INC. TO HOST FOURTH QUARTER AND FULL YEAR 2006 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS CONFERENCE CALL

Wilmington, MA - March 13, 2007 - DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its corporate highlights and year end financial results press release will be issued on Friday, March 16th at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

Friday, March 16th - 8:30 a.m. Eastern
If calling from the US or Canada use the following toll-free number:
800.647.4314
Password - DUSA

For International callers use
641.297.7663

A recorded replay of the call will be available
North American callers 877.863.0350
International callers 858.244.1268

The call will be accessible on our web site approximately 1 hour following the call at www.dusapharma.com.

About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. is an integrated dermatology specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of pre-cancerous actinic keratoses, and is being developed for the treatment of acne. DUSA's other dermatology products include Nicomide®, and the AVAR® line. These products target patients with acne and rosacea. DUSA is also developing certain internal indications of Levulan PDT. DUSA is based in Wilmington, MA. 

For further information contact:
Shari Lovell, Director, Shareholder Services
Tel: 416.363.5059